Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept Eye Drops for Corneal Neovascularization
NCT04215393Phase 1Unknown
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Jul 2019
- Primary completion
- Apr 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised trial of conbercept in corneal neovascularization (CNV) (3 arms), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Primary endpoint: Ocular and Systemic Safety at 14 days. Status: unknown.
02
Drugs
conbercept
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on NCT04215393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215393.